Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Energy couldn’t agree more. The last time I, and the market was surprised positively by an rns was April 8th 2020. 4 years without a rerate rns just slow steady progress. The traders have been allowed to trade with impunity taking many longer term traders to the cleaners. But that will change and that change just might be quicker than the market seems to think. The catalyst to get those deals over the line I believe will be 2W Progress. Improved patient experience will be obvious
Comments based on knowledge actually and 14 years of shareholding. The chairman is rebuilding a management team at board level which will have a completely different emphasis and expertise. Chris is just the first piece in the puzzle.
2W the first patient was dosed before Christmas it was quote a ‘mistake’ not to announce. There are a considerable number (sadly) of STS patients under MSK’s care. The low recruitment of the second and third candidate was apparently due to a very strict criteria on exactly who they wanted on the trial. I will post this evening on why I think that is
Whether it’s the 2W phase, commercial deal, strengthening board or just buy out from this level surely this is a golden opportunity for retail investors to make some money. My message would be analyse the science, and just because it looks to good to be true doesn’t mean you cannot make your own informed decision. We are in discussion with big pharma (rumour Pfizer,Novartis & BMS) whether that turns into deals next week, next month or next year I have no idea but one would be transformational and I think it’s sooner rather than later…..BUT I have persuaded numerous family and friends to invest in Avacta and over the last few years have continuously got it wrong but this time Rodders we are nearly there. Of course DYOR
We have a clinically proven technology with now a growing list of independent clinicians putting their name to the pre|CISION technology. If the person who I believe is joining the board does join it will be a further endorsement of the technology not that it’s needed for anyone in the sector just for the market. What ever way you look at it we have a technology that has quote ‘every large pharma dropping by the stand at AACR. Whatever happens we have 12 months of cash
Think I meant Chris. So why have I started posting more. I have known Alastair along time and over the years have had frequent conversations with him. Never has he given any ‘insider’ information, but nevertheless I have had a probably more complete picture than most. I think Alastair was Avacta’s greatest strength but for legacy issues (his company’) and his lack of commercial experience and understanding of the market and the city he had become its greatest weakness. Now Eliot has to step up and build an experienced commercial management to prove he is not part of the problem. He certainly bears part of the responsibility
Give Chis a chance…….Whereas I agree with the sentiment I think it’s misleading. This is not just a new ceo this the first step in a complete transformation of the reason to be for Avacta. The emphasis will now be focused on the science (from an oncologist ceo) and commercialism in the near future of that now proven science. The board will be enhanced and the expertise recruited to realise that goal. This is a complete sea change and the market does not understand the consequences. For new investors at this level an opportunity for multiple returns for us longer term shareholders a nice return probably this year but maybe not the mega returns we dreamed about
I think, for what it’s worth, change was necessary and as Eliot intimated further additions are already in motion. I believe I know the next name in the frame and if correct he will bring a wealth of commercial experience and ‘gravitas’ to the management of Avacta. On one side we have what is now being continuously confirmed as a game changing technology platform. With the sp at these levels the joke is on us. We now need a deal making commercial team who can maximise the opportunity to big pharma sector AND a commercial team who understands the global funding opportunities that we will begin to have.
Last century when I’d naively got myself in a bit of business bother my south London solicitor said ‘you’ve turned round, pulled your trousers down and bent over and now wonder why you’ve been shafted. In the placing I was made inside and told the placing price was 75p but then I was blatantly encouraged to put in a speculative order at 50p because nod nod wink wink. In this market if you ask to get shafted you will…..but then don’t be surprised when it happens
This valuation is simply Unbelievable. An (independent ) clinical proof of concept. This has got to be the biggest opportunity for serious returns on AIM for years. There’s an old saying about investment. ‘Buy when there is blood on the streets even if some of it is yours’
We have a minimum of 1 year cash, even with loss on diagnostics make that 2 years. Listen to the webcast and make an informed investment decision. There is a ‘big hitter’ coming onto the board.
Hi Oldt
I believe Alastair has had every opportunity to build a strong commercial team, unfortunately he has not done so to date. Given that we now have ‘proof of concept’ for pre|CISION surely the only explanation for the current valuation is the market has no confidence that Alastair can commercialise the technology. The events of the last year have given some justification to that view. You state he is not a good ceo. Surely we now need a strong experienced commercial ceo?
Thanks DTW. I’m looking forward not back, therefore is the question do we have a commercial team in place to maximise value for shareholders? I would like to add if we are genuinely standing on the verge of a potential paradigm shift in the treatment of many cancers from the moral standpoint do we have the deal making team in place to ensure multiple deals are agreed with big pharma to ensure as many treatments as possible can be made available to as many patients as possible as quickly as possible. The answer simply is what team? If Alastair was lacking in commercial experience then he could have built a comprehensive and experienced team around him. I believe we are talking about deals eventually worth billions of dollars. Given the data is providing proof of concept we need an experienced ceo and board who can work together to build the experienced commercial teams required. That is why I believe we need the change that I am told will happen next week.
It is of course all personal opinion which makes a chat board worthwhile. Firstly next week is not an AGM that’s in Summer. Secondly I am a percentage holder, least I was 😂 so after 14 years am very much looking at the bigger picture. I believe Alastair to be a man of genuine integrity and can only praise the tech he has acquired for Avacta. But and it is a very large BUT commercialism has not followed on any front. We were promised commercial turning points in 2015 / 2016/ 2017 with various diagnostics, then Affimers, then TMAC, then Covid LFD now pre|CISION. I think in deference to Alastair and his character long term shareholders have given him every latitude. The last few months have, as they say, been just been the final straw that broke the camels back.
As to senior staff rotation / loss. It is often not a good thing but if you think about it that’s exactly what we’ve had under Alastair’s tenure. The CFO is one of the only one’s to survive and I certainly have a view on that.
Discussion boards are for discussion and exchange of knowledge. I hope this thread promotes discussion of different points of view. Sensible views are all valid.
My personal belief is that a considerable number of ‘commercial’ errors of judgement have been made over the last few years. The board and particularly the chairman have a duty of care to ensure on our behalf that the company is well run. If mistakes are made by the ceo then the board shares the responsibility. It has always been a major red flag tome that the board members have never seen fit to support the company with reasonable share purchases. If they do not believe in the company why should investors new and old?
Like it or not management change will take place next week. The board is culpable for the appalling loss of value over the last 5 months but finally I hope the board will act responsibly and ensure a smooth transition. Sadly over the last few years for most of the long term shareholders it has become increasingly obvious despite the science that a lack of commercial leadership would be our Achilles heel. Possibly more by luck than judgement we have arrived at the 2W phase of the trial with our assets intact and despite the recent unacceptable dilution this may yet prove to be the most value enhancing strategy. Only time will tell. Whatever happens I’ll leave to my crystal ball however for sure a new chapter for Avacta starts next week.
April 2022 on a visit to White City, standing on the terrace with Fiona, Neil and Alastair and yes for those who don’t believe it you can see one of the Novartis buildings. I was asking why don’t you de-risk trial by taking partner. Neil said then ‘we know what we’ve got (we don’t need anyone else to tell us) and we)re not going to give it away’ If they knew then 2 years more of data can only reconfirm. For once let us hope that Avacta ‘Blow the bloody doors off’ but I suspect it will just be another step forward while we await the big pharma deals that give us the third party validation we crave.
I’ve posted this before and hope it’s relevant. I have been invested a long time and got our LFD scenario (fiasco) completely wrong. I am extremely unhappy about the last few months to put it mildly and without expletives. There may have been partially mitigating circumstances (always need a plan B) but we may never hear the truth on that one. So I go back to April 2022……